title: A new approach to dose reduction in chronic schizophrenia.
abstract: The bromocriptine growth hormone test (BGHT) was used to monitor D2 receptor activity in a group of 16 chronic schizophrenics who during the baseline phase were receiving greater than or equal to 20 mg/day haloperidol. In all subjects at baseline, the rise in plasma GH in response to the oral administration of bromocriptine (50 micrograms/kg) was blocked. The dose of haloperidol was then gradually reduced; the BGHT was repeated as each new dose was established. No escape from blockade of the GH response was observed until the dose of haloperidol was lowered to 10 mg/day (3 of 16 subjects escaped from blockade). At this dose the average plasma haloperidol level was 4 ng/ml. Two additional subjects escaped as the dose was reduced to 5 mg/day and six more escaped as the dose was reduced to 2.5 mg/day. The average haloperidol plasma level at 5 and 2.5 mg/day was 1.6 and 1.2 ng/ml respectively. The remaining five subjects escaped from blockade as the dose was reduced to 0 mg/day. In five subjects, escape from blockade was associated with a significant decrease in positive psychotic symptoms; in these subjects reestablishing the "just" blockade dose of haloperidol did not increase psychotic symptoms. In nine subjects escape from blockade was associated with an increase of positive psychotic symptoms; in six of these patients, reestablishing the "just" blockade dose of haloperidol attenuated psychotic symptoms to near baseline levels. We conclude that the GH challenge test is a useful adjunct to dose-reduction in the chronic patient. Furthermore, for some patients the "just" blockade dose appears to be near the minimum dose with the maximum therapeutic effect.
authors.affiliation: Psychiatry Service, VAMC, Northport, New York.
authors.forename: J
authors.initials: J
authors.lastname: Hirschowitz
authors.forename: R
authors.initials: R
authors.lastname: Hitzemann
authors.forename: G
authors.initials: G
authors.lastname: Burr
authors.forename: A
authors.initials: A
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000008:administration & dosage; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D013006:Growth Hormone / Q000097:blood; D006220:Haloperidol / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000502:physiology; D017448:Receptors, Dopamine D2; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D013006:Growth Hormone; D006220:Haloperidol